| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
We analyzed the expression of proteins in salivary gland cancer. The results showed that the expression of EGFR, HER2 and c-KIT was 76%, 20% and 38%, respectively. Among them, the patients with HER2-positive tumors had significantly unfavorable prognosis. Furthermore, we found the activation of the PI3K pathway in HER2-positive tumors. HER2 was mainly overexpressing in salivary duct carcinoma, and was detected more frequently in carcinoma ex pleomorphic adenoma than in de novo tumors. This result suggested that HER2 could be involved in carcinogenesis from pleomorphic adenoma. Based on these results, we planned to develop a HER2-targeted therapy in salivary gland cancer.
|
